• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Ferring Pharma acquires Rebiotix and its microbiome therapy platform

April 5, 2018 By Sarah Faulkner

RebiotixFerring Pharmaceuticals inked a deal to acquire Rebiotix and its platform of living drugs for an undisclosed amount, the companies announced today.

The Roseville, Minn.-based company is developing a microbiome-based therapy to prevent recurrent Clostridium difficile infection. Its Microbiota Restoration Therapy, which is delivered via enema or a lyophilized, non-frozen oral capsule, is designed to supply a patient’s intestinal tract with an array of healthy, human-derived microbes.

The company’s most advanced candidate, RBX2660, is in Phase III development and, if approved, would be the first human microbiome product on the market. The FDA granted RBX2660 fast track, breakthrough therapy and orphan drug status.

“The scientific advances Rebiotix has made add significant strategic value to Ferring’s leadership in gastroenterology,” Michel Pettigrew, executive board president & COO of Ferring Pharmaceuticals, said in prepared remarks. “Therapies targeted towards the microbiome have the potential to transform healthcare. Together, we have a unique opportunity to help people living with debilitating and life-threatening conditions like Clostridium difficile infection.”

“Ferring shares our passion for understanding the role the microbiome plays in human health and has global capabilities that offer huge potential for the investigational therapies that we have in development,” founder, president & CEO of Rebiotix, Lee Jones, added. “Rebiotix was founded to revolutionize healthcare by harnessing the power of the human microbiome and this is a significant milestone in achieving that goal.”

More than 500,000 people are infected annually with C. diff., according to Rebiotix, and up to 30% of C. diff. patients experience more than one episode and need repeat treatment.

“The key is that there’s an underlying condition generally that’s caused them to be susceptible to C. diff. in the first place,” Jones told Drug Delivery Business News in an interview last year. “So what we’re doing with this disease is we’re dealing with the whole person.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Mergers & Acquisitions, Pharmaceuticals Tagged With: ferringpharmaceuticals, rebiotix

IN CASE YOU MISSED IT

  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set
  • Glucotrack can proceed with long-term glucose monitor study in Australia
  • Dexcom promotes Jake Leach to president role
  • Roche invests $550M to make Indianapolis a CGM manufacturing hub

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS